Understand the evidence
How much do the studies tell us?
Read the result and the limit together. A hopeful result can still leave cause and effect unsettled.
The research has limits
The September 30, 2026 evidence review found small human studies, with much of the patient research published in Russian.
Language does not decide whether a study is sound. It can affect whether the full work was available for review.
FDA left the Russian stroke papers out of its review because the complete papers were not available in English.
A search checked on September 30, 2026 found no Semax study in ClinicalTrials.gov, the US public study register.
Stroke findings do not settle cause
Russian stroke reports described better recovery in groups receiving Semax alongside their usual treatment.
These results come from English abstracts, the short summaries of the Russian papers. The complete papers were not read for this guide. The summaries did not explain whether chance determined which group each person joined. They also did not say whether patients or researchers were kept from knowing who received Semax.
Without those details, the reported improvement does not show that Semax caused it.
FDA's July 2026 review found too little evidence to support Semax for brain injury from reduced blood flow, migraine or severe facial nerve pain.
Pain research was also thin
FDA found a small pain study with no group receiving a different treatment or no treatment to compare with the Semax group. Without that comparison, the study cannot separate Semax's effect from changes that might have happened anyway. Most people with migraine headaches still had pain. People with facial nerve pain showed no change.
FDA's review also notes that approved treatments exist for the conditions it assessed.